The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...
Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca's IL-33 blocker AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
It’s been a little over two months since President Donald Trump’s direct-to-consumer pharmaceutical site, TrumpRx, launched, ...
Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic ...
So far, TrumpRx lists fewer than 60 drugs, mostly brand-name medicines. Many already have cheaper generic versions. HealthDay News — TrumpRx, the president’s discount program for prescription drugs, ...
A new study published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation shows how an innovative phone-based inhaler education program helped Medicare Advantage ...
(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...
Shares of AstraZenecaAZN rose nearly 3% on Friday after the company announced that its experimental monoclonal antibody, tozorakimab, met the primary endpoint in two phase III studies for chronic ...
AstraZeneca shares were up about 3.5% Friday after the company said its drug for COPD, a deadly lung disease often caused by smoking, slowed patients' symptoms in two large trials. The drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results